Prime Medicine (PRME) Common Equity (2021 - 2026)

Prime Medicine has reported Common Equity for 6 years, with the latest figure at $76.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 28.27% year-over-year to $76.7 million; the trailing twelve-month figure through Mar 2026 stood at $76.7 million (down 28.27% YoY), and the FY2025 full-year result was $120.9 million, down 21.08% from the prior year.
• Common Equity for Q1 2026 stood at $76.7 million, down from $120.9 million in the prior quarter.
• The five-year high for Common Equity was $316.3 million in Q4 2022, with the low at -$223.1 million in Q3 2022.
• Historically, Common Equity has averaged $111.0 million across 5 years, with a median of $153.1 million in 2024.
• The largest YoY upside for Common Equity was 302.43% in 2022 against a maximum downside of 136.29% in 2022.
• Prime Medicine's Common Equity stood at $316.3 million in 2022, then slumped by 57.92% to $133.1 million in 2023, then advanced by 15.09% to $153.1 million in 2024, then decreased by 21.08% to $120.9 million in 2025, then slumped by 36.54% to $76.7 million in 2026.
• The last three Common Equity figures came in at $76.7 million (Q1 2026), $120.9 million (Q4 2025), and $161.8 million (Q3 2025), per Business Quant data.